Sven Rottenberg, DVM, PhD, Dipl. ECVP
Comparative pathology, genetically engineered mouse models of breast cancer, anti-cancer drug resistance
Sven Rottenberg received a dual education in veterinary pathology and molecular biology at the University of Bern. During his PhD in the group of Dirk Dobbelaere he elucidated interactions between the intracellular parasite Theileria and the host cell signaling pathway. After finishing his pathology training (Dipl. ECVP) in 2004, he joined the group of Piet Borst at the Netherlands Cancer Institute (NKI) in Amsterdam where he became an independent group leader in 2012. At the NKI Sven Rottenberg established a new research focus in collaboration with the group of Jos Jonkers: the study of drug resistance using genetically-engineered mouse models (GEMMs) of human cancer. In 2014 Sven Rottenberg returned to Bern as head of the Institute of Animal Pathology.
The comparative pathology research of Sven Rottenberg focuses on 3 major topics that hamper the success of anti-cancer drug treatment: identification of markers that predict therapy response, illuminating mechanisms of acquired drug resistance, and understanding why it is so difficult to eradicate drug-sensitive tumors. For this purpose GEMMs of human breast cancer are studied using drugs that are frequently used in the clinic. Moreover, novel therapeutic compounds and genetic targeting of putative genes involved in drug resistance are tested to circumvent or reverse resistance.
For a full list of publications, please see: